Mr Marco Estermann, head issuer relations, SIX Swiss Exchange
The SIX Swiss Exchange has over $450 billion of free-float market capitalization representing over 40 percent of the European market.
The Swiss capital market makes available a deep pool of capital for companies wanting to diversify their investor base. Out of $5.5 trillion assets under management in Switzerland, about $2.2 trillion is allocated to shares.
Sector champions like Novartis, Roche, and Actelion Pharmaceuticals are listed on the Exchange, and other global pharma giants such as Pfizer, Abbott, and Eli Lilly are secondary listed and traded. In addition to international global investors, two unique investor classes can be accessed via a listing on SIX.
Representatives from the Exchange regularly travel to India to meet with interested listing candidates, advisors, and owners of businesses, for example, private equity funds.
"A listing on SIX would allow an Indian company to be included in the same benchmark indices as other sector champions, which would enhance trading liquidity as well as impact credibility positively. Switzerland has the world's highest number per capita of biotech and medtech companies thereby giving companies visibility among an audience of investors with high expertise in the sector, and attract professional and extensive coverage through numerous analysts. At the same time a life science company that lists on SIX would also get a relatively higher level of visibility and media attention (scarcity value) compared to for instance the US markets," explained Mr Tarun Gupta, official, SIX Swiss Exchange, India representative.